|

Tunlametinib+PD-1 mAb Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Fudan University1

Indications

  • Advanced PDTC or ATC With NRAS Mutation1
  • Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation1
  • Cancer1

Other1 trial

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.